Intriguingly, according to the clinical data, we found that there is significant sex disparity in the pharmacological effects of FG-4592: it can only relieve DKD in males, presented as significantly lower SBP, DBP, and serum Cr, and higher serum Hb and eGFR. This evidence concerns the gene GSTM1 and diabetic kidney disease.